
Senti Biosciences Investor Relations Material
Latest events

Status Update
Senti Biosciences

Q2 2025
7 Aug, 2025

Q1 2025
6 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Senti Biosciences Inc
Access all reports
Senti Biosciences Inc. is a biotechnology company engaged in developing innovative cell and gene therapies. The company specializes in the use of gene circuit technologies, which involve designing and programming cells to function as intelligent medicines capable of addressing various diseases. Senti Biosciences’ platform focuses on three main areas: off-the-shelf CAR-NK cells for oncology, gene therapies targeting specific tissues, and cell therapies for regenerative medicine. Their lead product candidates include therapies targeting different types of cancer using CAR-NK cells engineered with these gene circuits. Senti Biosciences is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
SNTI
Country
🇺🇸 United States